Sunitinib Treatment for Advanced Paraganglioma: Case Report of a Novel SDHD Gene Mutation Variant and Systematic Review of the Literature

Franz Sesti, Tiziana Feola, Giulia Puliani, Roberta Centello, Valentina Di Vito, Oreste Bagni, Andrea Lenzi, Andrea M. Isidori, Vito Cantisani, Antongiulio Faggiano and Elisa Giannetta

Background: Paragangliomas (PGLs) are neuroendocrine neoplasms arising from chromaffin cells of sympathetic or parasympathetic paraganglia. Systemic therapies have been used only in metastatic PGLs. Antiangiogenic agents, such as sunitinib, could be a viable therapeutic choice in the subgroup of patients with SDH-positive PGLs. We describe the case of a man with Familial Paraganglioma Syndrome type 1 (FPGL) related to a novel mutation in SDHD gene treated with sunitinib. Furthermore, we performed a systematic review of the literature aimed to address the following question: is sunitinib treatment effective in patients with advanced/progressive/metastatic PGL?

Methods: We performed a data search using MEDLINE, Cochrane Library, and Scopus between April 2019 and September 2020. We included studies reporting data on clinical or biological characteristics, or clinical outcomes of patients with PGLs treated with sunitinib.

Results: The search led to the selection of 25 publications. Data from case reports and case series showed that disease control rate (DCR = stable disease + partial response + complete response) was achieved in 34.7% of cases under sunitinib treatment. In 39% of patients DCR was followed by progressive disease (PD) or tumor relapse, 26.1% patients showed PD. Data from clinical trials showed that DCR was 83%, and the median progression free survival was 13.4 months.

Discussion: Data from the present literature review suggested that sunitinib could be a viable therapeutic option in advanced/progressive/metastatic inoperable PGLs. However, further trials on the efficacy of sunitinib in FPGL and sporadic PGL are needed.

Keywords: sunitinib, paraganglioma, Familial Paraganglioma Syndrome, succinate dehydrogenase, SDHD
INTRODUCTION

Paragangliomas (PGLs) are neuroendocrine neoplasms (NENs) arising from chromaffin cells of sympathetic or parasympathetic paraganglia (1). A germline mutation is found in approximately 40% of these tumors (2). Both in sporadic and inherited PGLs, it is possible to evidence two different pathogenetic pathways: alterations in proteins associated to Krebs cycle and hypoxia signaling (cluster I), and alteration in kinase signaling (cluster II) (3). Cluster I includes mutations in genes like von Hippel–Lindau (VHL), 2-oxoglutarate-dependent prolyl hydroxylase (PHD2), and succinate dehydrogenase (SDH), which is a component of the electron transport chain of the Krebs cycle and catalyzes the oxidation of succinate (4). Catalytic core of SDH is made of 2 subunits (SDHA, SDHB), anchored to the mitochondrial inner membrane through subunits SDHC and SDHD (5). Mutations in a subunit of SDH determine an accumulation of succinate, which causes an increase of hypoxia inducible factor (HIF) 1α for a reduction of its ubiquitination (6). The elevation in HIF1α leads to activation of the angiogenic pathway and alteration in cell metabolism (7).

SDHD mutations are responsible for Familial Paraganglioma Syndrome type 1 (FPGL1), inherited in autosomal dominant manner, characterized by head and neck parasympathetic PGLs (85% of cases), more rarely thoraco-abdominal sympathetic PGLs (20–25% of cases) and pheochromocytomas (10–25%) (8, 9). Some 157 mutations have been described in SDH gene, including deletions and duplications (an updated list is available at https://databases.lovd.nl/shared/genes/SDHD) (10).

Malignant head and neck PGLs are extremely rare (8, 11). However, their local growth can determine compression and/or infiltration of the neighboring anatomical structures, causing dysphagia and cranial nerves palsy (12). Surgery represents the first-choice treatment for head and neck PGLs (13), but severe complications, including cranial nerve lesions and vascular damage can occur (14).

Systemic therapies have been used in metastatic PGLs only (15). Antiangiogenic agents, such as tyrosine kinase inhibitors (TKI), have demonstrated in a phase 2 trial to determine disease stability, as well as partial response in the subgroup of patients with SDH-positive PGLs (SDHA and SDHB) (16).

The effectiveness of sunitinib, a widely used TKI, in patients with advanced/progressive/metastatic PGL is still unclear. Starting from the observations in our clinical case, the present systematic review is aimed to address the following question: is sunitinib treatment effective in patients with advanced/progressive/metastatic PGL?

CASE PRESENTATION

On September 2018, a 37-year-old man contacted the Neuroendocrine Tumor task force Unit (NETTARE) of the Policlinico Umberto I Hospital at “Sapienza” University for the appearance of bilateral laterocervical swellings three years before, diagnosed as PGLs. He smoked for 15 years. His personal history includes allergic asthma and coccygeal fistula surgically treated in 2003. The patient had a familial history for neoplasms on the father’s side: a grandmother with a non-better classified parathyroid neoplasm and a grandfather with a history of thyroid, bladder, and gastric cancer.

On clinical examination left lateral cervical mass was fixed and firm, and no other relevant alterations were found. He reported dysphagia and dyspeptic symptoms without other disturbances; blood pressure and heart rate were normal.

The patient’s clinical history began in December 2015 when, for the appearance of bilateral laterocervical masses, he performed a magnetic resonance (MR) imaging of the neck that highlighted “the presence of two expansive lesions localized bilaterally in the vascular spaces of the neck, on the right of 45 × 25 × 70 mm and on the left of 48 × 44 × 53 mm, with an inhomogeneous architecture, and a marked and inhomogeneous contrast enhancement”. The MR angiography confirmed the vascular nature of the masses. The right lesion extended from the carotid bifurcation growing cranially up to the lacerated foramen, determining encasement of the internal and external carotid arteries, located both anteriorly. This formation exerted an evident mass effect in the retro-stylous vascular space, causing the lifting of the muscular tent of the upper constrictor and the partial distortion of the oropharyngeal air column. The left lesion surrounded the middle distal tract of the common carotid artery, determined encasement of two branches at the carotid bifurcation, but involved only the cervical tract of the internal carotid artery. Biochemical assessment showed negative urinary metanephrines (44 μg/24 h, range 20–345).

After two different multidisciplinary consultations, on September 2016 the patient underwent the removal of the right lesion after embolization, with histological examination compatible with PGL: “neof ormation of 44 mm, consisting of solid round nests of monomorphic cells of medium-sized, immunoreactive for chromogranin A, synaptophysin, vimentin, negative for EMA, CAM5.2, AE1/AE3. At the periphery, cellular component of dendritic aspect, S100 positive. Ki67 index <2%”. After surgery, the patient reported a lesion of the right hypoglossal nerve, developing right vocal cord hypo-mobility, paresis of the palatine veil on the right side, right hemilinguinal hypotrophy, and a complete deficit of tongue mobility. In March 2017, the left lesion was embolized.

During the follow-up the patient performed several morphological and functional imaging exams. The MR and computed tomography (CT) angiography confirmed the presence of residual tissue on the right side of 15 mm, whereas the embolized lesion on the left appeared slightly reduced in size compared to the pre-operative examination (40 × 43 × 53 mm), with presence of vital tissue. Both lesions showed significant uptake of radiotracer at 18F-fluoro-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET)-CT with a SUVmax of 10.5 on the left and 5.66 on the right, and at 68Ga-DOTA-D-Phe1-Tyr3-Octreotate (68Ga-DOTATOC) PET-CT (Figures 1A, B). Moreover, the latter showed a further area of focal uptake in correspondence of the skull base on the right, adjacent to surgical clips.
Considering the expression of somatostatin receptors, in December 2018 a therapy with somatostatin analogs (SSAs) was started (lanreotide 120 mg every 28 days subcutaneously). The patient experienced poor tolerance because of abdominal pain and acholic feces, so the dose was reduced to 90 mg every 28 days until the disappearance of the symptomatology. At 4-month MR angiography, tumor growth was observed (the right measured $22 \times 15$ mm; the left $69 \times 46 \times 50$ vs $40 \times 43 \times 53$ mm). A 18F-fluorodeoxyglucose (FDG) PET-CT was performed according to our proposed follow-up algorithm (17), with evidence of an intense metabolic activity in correspondence of the left voluminous expansive lesion (SUVmax 26.6) and the known right nodular lesion (SUVmax 27.4).

Given the morpho-functional features of the lesion (local aggressiveness, progression, high 18F-FDG uptake), the risk-effectiveness of the treatments’ strategies (high surgical risk, potential ineffectiveness of radiotherapy due to high tumor volume, poor efficacy and tolerance of SSA administration), and patient preferences, the NETTARE multidisciplinary board proposed a targeted therapy with a TKI: sunitinib.

In October 2019, sunitinib was started at a low dosage (25 mg daily orally), in order to minimize the potential toxicity, obtaining a relevant clinical response, with improvement of dysphagia and pain, and consequent improvement of quality of life. A good safety profile was reported. The follow-up with contrast-enhanced ultrasound (CEUS) of the neck showed a precocious size reduction of the lesions with onset of necrosis signals. The left lesion was decreased from $57 \times 48$ mm at baseline to $47 \times 31$ mm at 20 days and then was stable at 50 days, the right lesion was decreased from 13 mm at baseline to 9 mm at 20-day follow-up and then stable at 50-day follow-up. Near the end of the third cycle of sunitinib a 18F-FDG PET-CT with contrast medium was performed. The peak standardized uptake value corrected for lean body mass (SULpeak) of the left lesion was reduced by 18% (Figures 1C, D). Subsequently, a MR angiography performed at one-year follow-up showed the right lesion decreased to from $16 \times 22 \times 11$ mm to $19 \times 13 \times 20$ mm and left lesion decreased from $69 \times 46 \times 50$ mm to $59 \times 46 \times 51$ mm. At last MR follow-up in March 2021, right and left lesions were stable measuring respectively $18 \times 16 \times 13$ mm and $60 \times 44 \times 47$ mm. Thus, under sunitinib treatment the patient has been stable for 17 months (Figure 2).

Previously, the patient underwent a genetic consultation with the detection of a new mutation of SDHD gene c.16_28del p. Arg6PHEFS*5, that has never been described in literature, consistent with the diagnosis of FPGL1. A complete family history was collected in spite of the absence of other familial cases of PGL. At the genetic test among the first-degree relatives, the brother was negative, while the father was SDHD mutated. He underwent a neck and chest CT, that showed a lesion on the left carotid (max diameter 24 mm) as well as an enormous lesion in the mediastinum (>100 mm of maximal diameter), both with marked contrast enhancement. The 68Ga-DOTATOC PET-CT and 18F-FDG PET-CT were performed, highlighting uptake of both the radiotracers. The mediastinum lesion was removed after embolization by an expert team of thoracic surgeons of our Unit. The histological diagnosis was consistent with PGL: neoformation of $100 \times 90 \times 40$ mm, associated to another neoformation of 15 mm with the same characteristics in
proximity of the main lesion. Both neoformations consisted of organoid nests of medium-sized cells with a large clear cytoplasm and a dispersed chromatin oval nucleus, which in the smaller lesion is hyperchromatic and irregular, surrounded by a thin continuous line of spindle cells with an elongated nucleus, and separated by a dense capillary vascular network. Immunochemistry was positive for synaptophysin, CD56, S100, GFAP, and weakly positive for chromogranin A. Ki67 index was 4%.

**METHODS**

A systematic review was performed following a rigorous protocol based on the Cochrane Collaboration and PRISMA statements (18, 19), in order to address the following question: is sunitinib treatment effective in patients with advanced/progressive/metastatic PGL?

English-language original articles were independently searched by one author (FS) in several databases (MEDLINE, Cochrane Library, and Scopus) between April 2019 and September 2020. The following key words were used for study search: (sunitinib AND paraganglioma) OR (sunitinib AND paraganglion tumor) OR (sunitinib AND paraganglionic tumor) OR (sunitinib AND paraganglionic neoplasm) OR (sunitinib AND paraganglionic neoplasm). Additional articles were identified by hand-searching reference lists of all the eligible articles retrieved.

The titles and the abstracts of all identified articles were independently screened by one reviewer (FS) to assess their relevance. Reviews, animal studies and non-original articles were excluded. Full texts of selected, potentially relevant, papers were further evaluated. For the purpose of this review suitability of studies was defined as eligible if reporting data on the clinical or biological characteristics, or clinical outcomes of patients with PGL treated with sunitinib. We therefore selected studies that met all the following eligibility criteria: (i) randomized-controlled trial, prospective or retrospective studies, case series or case reports; (ii) PGL diagnosis; and (iii) treatment with sunitinib.
One author (FS) independently extracted the following data from included publications: first author, year of publication, study design, age, sex, primary tumor site, mutation status, sunitinib schedule, radiographic response criteria, radiographic response, response duration, and toxicity. Table 1 summarizes these data.

RESULTS

Some 150 potentially relevant studies were identified, 116 were excluded on the basis of title and abstract screening. The main reasons for exclusion were not original studies, reviews, animal studies, duplicates, lack of group of interest (treatment with sunitinib). Of the 34 remaining publications, nine were excluded after full text assessment because they did not meet all the eligibility criteria. This process led to the selection of 25 publications (Figure 3) (16, 20–43).

Case Series and Case Reports

Data about objective response were available for 23 patients (nine women and 10 men, sex was not available for four patients) (Table 1). The patient age range was 20–77 years. Cumulative mean age, and cumulative median age were 45 and 47 years, respectively. In all cases disease status at baseline was represented by progressive or inoperable disease. Metastases were present in all patients. Some 14 patients had abdominal PGL, three head & neck PGL, and two pelvic PGL.

Mutation status was examined in 18 patients showing: SDHB (n = 15), MAX (n = 1), and SDHC (n = 1) mutations; one patient had sporadic PGL.

Treatment schedule included sunitinib regimens using 50, 37.5 or 25 mg. Six patients (26.1%) showed progressive disease (PD), four patients (17.4%) showed disease (SD), three patients (13%) showed (PR), two patients (4.3%) patient complete response (CR), two patients (8.7%) SD followed by PR, six patients (26.1%) PR followed by PD, one (4.3%) CR followed by relapse.

Regarding previous therapy, 16 patients underwent surgery before sunitinib treatment, 10 were treated with chemotherapy, six with radiotherapy, five with 131I MIBG, three with octreotide, two with PRRT, and one with everolimus. Only two patients started sunitinib as a first-line therapy. Data about objective response in this subset were available for two patients, one patient showed PR followed by PD, and one patient showed SD. In six cases sunitinib was used as first-line systemic therapy after surgery, four patients showed PR followed by PD, and two PD. In one case sunitinib was the first-line systemic therapy after surgery and radiotherapy, the patient showed PR. In any other case sunitinib was prescribed after one or more systemic therapies.

Clinical Trial

The only clinical trial available in the literature has been published by O’Kane et al. (16) who evaluated the effects of first-line sunitinib treatment (50 mg orally, daily for 4 weeks, followed by 2 weeks observation) in 25 patients (14 men and 11 women) with non-resectable or metastatic progressive PGL (11) or pheochromocytoma (14). Median age was 50 years (range: 17–79 years). Five patients were SDHB mutated, one SDHA, one SDHC, one RET, and one MAX. The disease control rate was 83% (95% CI: 56–93%), including three patients who achieved a PR, and 16 with SD. The median progression free survival (PFS) was 13.4 months (95% CI: 5.3–24.6) (16) (Table 1).

DISCUSSION

In the present case report, the patient presented bilateral neck PGLs, the right lesion has been removed surgically, however a permanent lesion of the right hypoglossal nerve has occurred. After surgery, the patient still complained dysphagia and pain related to the left PGL. Therefore, given the high surgical risk due to the dimension and the localization of the left lesion, and the patient’s preference, a medical therapy has been proposed.

Current guidelines are lacking therapeutic options for patients with inoperable neck PGLs (13). The established localized treatments include external beam radiotherapy (44), radiosurgery (45), and ablative therapy (46). Whereas systemic therapies include radionuclide therapy with 131I-metaiodobenzylguanidine (MIBG) (47) or peptide receptor radionuclide therapy (PRRT) (48), chemotherapy with cyclophosphamide, vincristine and dacarbazine (CVD) (49), or temozolomide (50). Among molecular targeted therapies the efficacy of TKI as lenvatinib (NCT03008369), cabozantinib (NCT02302833), nivolumab, and ipilimumab (NCT02834013) are currently being evaluated in clinical trials (51). Recently, data from a phase 2 clinical trial provided the rationale for pembrolizumab use in patients with advanced PGLs (52).

Somatostatin receptors (SSTRs) are expressed by PGLs (53, 54), as confirmed by studies investigating 68Ga PET-CT role in PGLs diagnosis, staging, and follow-up (17, 55). Therefore, in our case, considering the 68Ga DOTATOC uptake SSAs were administrated (lanreotide 120 mg every 28 days). Currently, the efficacy of SSAs in PGLs has not been studied in phase 2–3 clinical trials, nevertheless, in a prospective intervention study, one of four patients with progressive head and neck PGLs treated with octreotide showed a reduced tumor growth (56). In the present case, the SSA was reduced because of side effects, then discontinued because of tumor progression.

Sunitinib has been chosen as a second-line medical therapy after a multidisciplinary consult. Sunitinib is a multitargeted receptor TKI which exerts antiangiogenic and antitumor effects targeting platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), KIT, and FLT3 (57). The rationale derived from the high expression of HIF1α, HIF2α, VEGF, and VEGFR arising from HIF dysregulation and hypoxia-inducible target genes’ activation, due to germline mutations of SDHD (58).
| Author and year | Sex | Age at diagnosis | Tumor site | Primary tumor dimension | Catecholamine excess | Mutation status | Previous therapy | Sunitinib schedule | Radiographic response criteria | Radiographic response | Response duration | Toxicity |
|-----------------|-----|-----------------|------------|-------------------------|---------------------|----------------|-----------------|-----------------|--------------------------|-----------------------|-----------------|----------|
| Joshua, 2009 (20) | M | 55 | Abdominal | 14.3 cm | No | SDHB | None | 50 mg daily for 4 weeks on, 2 weeks off (before surgery); 37.5 mg daily for 4 weeks on, 2 weeks off (after surgery) | RECIST | PR followed by PD | 24 weeks | Neutropenia, plantar-palmar erythema, fatigue, hypertension |
| Hahn, 2009 (21) | F | 33 | Pelvic | 7 cm | Yes | SDHB | Surgery, radiotherapy, cisplatin, etoposide | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | PR | 40 weeks | Mild anorexia, diarrhea, hypothyroidism |
| Cirillo, 2010 (22) | M | 37 | Abdominal | 17 × 14 × 9 cm | NA | SDHB | Surgery, dioxorubin, cyclophosphamide, vincristine and dacarbazine (modified CYVADIC), radiotherapy, 131I-MIBG, vinorelbine, octreotide, thalidomide | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | SD | 10 months | Hematuria, fever, abdominal cutaneous herpes, oral candidiasis, depressive syndrome, hypothyroidism |
| Zukauskaite, 2011 (23) | M | 31 | Head & Neck | 10 × 15 cm | No | SDHB | Surgery, doxorubicin, cyclophosphamide, vincristine and dacarbazine (modified CYVADIC), radiotherapy, 131I-MIBG, vinorelbine, octreotide, thalidomide | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | SD | 24 weeks | Fatigue, rash, neutropenia |
| Ayala-Ramírez, 2012 (24) | NA | 55 | NA | NA | Yes | SDHB | Chemotherapy | 50 mg daily for 4 weeks on, 2 weeks off or 37.5 mg daily continuously or 37.5 mg daily for 3 weeks on, 1 week off | RECIST | SD | 27 months | NS (Hypertension, diarrhea, hand-foot syndrome, sore mouth, fatigue, elevations of serum creatinine) |
| NA | 20 | NA | NA | Yes | SDHB | Chemotherapy | 50 mg daily for 4 weeks on, 2 weeks off or 37.5 mg daily continuously or 37.5 mg daily for 3 weeks on, 1 week off | RECIST | SD | 36 months | NS (Hypertension, diarrhea, hand-foot syndrome, sore mouth, fatigue, elevations of serum creatinine) |
| NA | 45 | NA | NA | No | SDHB | Chemotherapy, 131I-MIBG | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | PR | 4.5 months | NS (Hypertension, diarrhea, hand-foot syndrome, sore mouth, fatigue, elevations of serum creatinine) |
| NA | 40 | NA | NA | Yes | SDHB | Chemotherapy, 131I-MIBG | 50 mg daily for 4 weeks on, 2 weeks off or 37.5 mg daily continuously or 37.5 mg daily for 3 weeks on, 1 week off | RECIST | SD | 8 months | NS (Hypertension, diarrhea, hand-foot syndrome, sore mouth, fatigue, elevations of serum creatinine) |
| Bourcier, 2013 (25) | F | 70 | Abdominal | NA | No | NA | Octreotide, surgery | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | CR | 7 months | Hypotension |
| Prochilo, 2013 (26) | F | 35 | Abdominal | NA | No | SDHB | Surgery | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | PR followed by SD followed by PD | 9 months | Hypertension |
| Gillon, 2014 (27) | M | 49 | Abdominal | NA | Yes | NA | Surgery | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | PR followed by PD | 16 months | NA |
| Makis, 2016 (28) | F | 22 | Abdominal | 14 cm | NA | SDHB | Chemotherapy, 131I-MIBG | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | CR followed by relapse | 9 months | Gastrointestinal bleeding |
| Jeevan, 2016 (29) | F | 77 | Head & Neck | 2 × 3 cm | No | NA | Surgery, radiotherapy | 50 mg daily for 4 weeks on, 2 weeks off | RECIST | PR | 24 months | NA |
| Belgioia, 2016 (30) | F | 53 | Head & Neck | NA | NA | NA | Surgery, radiotherapy, PRRT | 50 mg daily continuously; 25 mg daily continuously | RECIST | PD | 10 months | Mucositis and fatigue |
| Canu, 2017 (31) | M | 35 | Abdominal | 4.6 × 4.9 × 5.9 cm | Yes | SDHB | Surgery | 25 mg daily for 2 weeks on, 1 week off | RECIST | PR followed by PD | 77 weeks | None |
| Patel, 2017 (32) | M | 47 | Abdominal | 10.8 cm | Yes | SDHB | Surgery | 37.5 mg daily continuously | RECIST | PD | 12 months | NA |
| Ferrara, 2017 (33) | F | 54 | Abdominal | 45 cm | Yes | MAX | None | 37.5 mg daily continuously | RECIST | PD | 4 months | Palmar-plantar erythrodysesthesia syndrome |

(Continued)
Table 1 | Continued

| Author and year | Sex | Age at diagnosis | Primary tumor site | Catecholamine excess | Mutation | Previous therapy | Sunitinib schedule | Radiographic response | Radiographic response duration | Toxicity | Radiographic response criteria |
|-----------------|-----|------------------|--------------------|---------------------|----------|-----------------|-------------------|----------------------|--------------------------|----------|-------------------------------|
| Ong, 2018 (34)  | F   | 51               | Abdominal          | NA                  | SDHC     | octreotide, everolimus | NA NA PD NA NA | NA NA PD 6 months Gastrointestinal side effects | NA NA PD 2 months NA | NA NA PD 2 months NA | NA NA PD 2 months NA | PERCIST 0 CR, 3 PR, 16 Median 50 SUV and 22 (11-79) SUV and 52 (17-93) |
| Stigliano, 2018 (35) | M   | 55               | Pelvic             | No                  | SDHB     | continuously; 25 mg daily continuously | 37.5 mg daily continuously | NA NA PD 24 months NA | NA NA PD 24 months NA | NA NA PD 24 months NA | PERCIST 0 CR, 3 PR, 16 Median 50 SUV and 22 (11-79) SUV and 52 (17-93) |
| Tena, 2018 (36)  | M   | 63               | Abdominal          | Yes                 | SDHB     | Surgery, cyclophosphamide, vincristine, and dacarbazine (CVD) | continuously; 37.5 mg daily continuously | NA NA PD 22 months NA | NA NA PD 22 months NA | NA NA PD 22 months NA | RECIST 0 CR, 3 PR, 16 Median 50 SUV and 22 (11-79) SUV and 52 (17-93) |
| Irwin, 2019 (37) | M   | 48               | Abdominal          | Yes                 | SDHB     | cisplatin/vinorelbine, 1 CVD, 1 chemotherapy, 1 surgery | 37.5 mg daily; 25 mg daily for 4 weeks, followed by 2 weeks observation | NA NA PD 3 months NA | NA NA PD 3 months NA | NA NA PD 3 months NA | PERCIST 0 CR, 3 PR, 16 Median 50 SUV and 22 (11-79) SUV and 52 (17-93) |
| Kane, 2019 (38)  | M   | 1               | Pelvic             | No                  | SDHB     | Surgery | 37.5 mg daily; 25 mg daily for 4 weeks, followed by 2 weeks observation | NA NA PD 3 months NA | NA NA PD 3 months NA | NA NA PD 3 months NA | RECIST 0 CR, 3 PR, 16 Median 50 SUV and 22 (11-79) SUV and 52 (17-93) |

Indeed, the tumorigenesis of PGLs seems partly related to a pseudo-hypoxic drive (59). These data support the rationale of this antiangiogenic therapeutic agent in PGLs.

Recently, O’Kane et al. evaluated the effects of sunitinib treatment on 25 patients with progressive PGL or pheochromocytoma in a phase 2 clinical trial (16). A disease control rate (DCR = SD + PR + CR) of 83% (95% CI: 56–93%) was obtained (16). Notably, three patients who had a PR carried germline mutations of SDHA, SDHB, and RET. Moreover, in four other patients with germline SDH mutations (three SDHB and one SDHC) a prolonged SD was achieved. No patient with SDHD mutation was included in the study (16). In our review a significant radiographic DCR was achieved in 34.7% of cases (SD in 17.4%, PR in 13%, and CR in 4.3%). In 39% of patients DCR was followed by PD or tumor relapse. Furthermore, 26.1% patients showed PD.

The discordant results between O’Kane et al. trial and our systematic literature review could be related to the inhomogeneity of the two populations. Indeed, 13 of 23 patients included in our review received two or more lines of therapy before sunitinib, while in the SNIPP trial only one patient received two lines of therapy. Moreover, patients in the SNIPP trial had PGL or pheochromocytoma, while in our literature review patients with pheochromocytomas were not included in the analysis. Furthermore, patients in the two populations received different sunitinib schedules.

The role of sunitinib in these patients could soon become clearer thanks to the First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPPP) trial, which is investigating the efficacy of sunitinib, at a starting dose of 37.5 mg daily, on the PFS of patients with progressive malignant PGL or pheochromocytoma (NCT01371201). Estimated study completion date of FIRSTMAPPP trial is June 2021.

In our case, the tumor response was early assessed by CEUS, according to previous studies (17). After 20 days of sunitinib therapy a SD was observed, the left lesion was reduced by approximately 10 mm and the right by 4 mm. In the subsequent CEUS evaluation after 56 days both lesions showed stable dimensions. Furthermore, the objective tumor response was accompanied by a clinical improvement of dysphagia and pain, leading to a better quality of life. The treatment has been well tolerated who did not report any specific side effect.

A previous study showed that 18F-FDG PET could be a reliable technique to evaluate tumor objective response in sunitinib treated PGLs (24). Indeed, all five SDHB-mutated patients with sympathetic PGL who were studied with 18F-FDG PET showed a PR or a SD according to RECIST 1.1 criteria (24). In a SDHB knockout mouse model of PGL treated with sunitinib, 18F-FDG PET was able to detect a transient reduction of FDG uptake and total lesion glycolysis (TLG) during the first two weeks of treatment. However, both SUV and TLG increased after the third week. Metabolic resistance preceded tumor growth which was evident after four weeks of treatment. This evidence suggests that 18F-FDG PET could monitor precisely metabolic changes of PGL during an
anti-angiogenic treatment and could possibly predict disease progression (60).

In the literature, to the best of our knowledge, among all patients with PGL treated with sunitinib, none was an SDHD mutation carrier, and none had a non-metastatic PGL (Table 1), making our patient the first case of SDHD-related benign PGL treated with sunitinib. Moreover, our patient showed a novel variant of SDHD gene, c.16_28del p. Arg6PHEFS*5, which is not described in the literature, neither present in genome (https://gnomad.broadinstitute.org) or in gene-specific databases (https://databases.lovd.nl/shared/genes/SDHD). The abovementioned variant is a small deletion of 13 nucleotides in exon 1 of SDHD gene, which determines a nucleotide sequence frameshift, resulting in a new aminoacidic sequence, starting from amino acid 6, with a premature stop after five amino acids. This variant has been classified as pathogenetic (class 5), according to American College of Medical Genetics and Genomics (61).

CONCLUSIONS

In the present paper we report the case of a patient affected by FPGL1 with locally-advanced bilateral neck PGLs. The peculiarity of the case lies in the fact that, to the best of our knowledge, this is the first reported patient with non-metastatic SDHD-related PGL treated with sunitinib. The treatment was safe and effective both in terms of tumor objective response and symptomatic relief. Moreover, both the patient and his father carry a novel mutation of SDHD gene, associated to the development of PGLs, never described in literature. On the basis of the reported pooled data from our systematic review, sunitinib could be a viable therapeutic option in advanced/progressive/metastatic PGLs, especially in patients with germline mutations. Further trials on the efficacy of sunitinib in FPGL and sporadic PGLs are needed.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

FS is the first author for this case report and systematic review of literature. EG is the corresponding author that concepted and designed the study. TF, GP, RV, OB, and CV contributed to the data collection, and manuscript, tables, figures preparation. CV, OB, AL, AI, AF, and EG revised critically this work. All authors contributed to the article and approved the submitted version.

FUNDING

Ministerial research project PRIN2017Z3N3YC.

ACKNOWLEDGMENTS

We wish to thank Dr. Stefania Zovato of the Familial Cancer Clinic and Oncoendocrinology Veneto Institute of Oncology IOV-IRCCS for identifying the novel heterozygous SDHD gene variant in the patient; Dr. Giovanni Savarese, Dr. Raffaella Ruggiero and Dr. Luisa Circelli of the Genetic Ames Group, Napoli, Italy for identifying the novel heterozygous SDHD gene variant in father’s proband.

We also wish to thank the NETTARE Unit—NeuroEndocrine Tumor TAsk foRcE of “Sapienza” University of Rome, Italy, led by Prof. Andrea Lenzi, Prof. Andrea M. Isidori, Prof. Antongiulio Faggiano, and Prof. Elisa Giannetta, for integrating the patient’s multidisciplinary clinical, diagnostic and therapeutic management, and follow-up.

REFERENCES

1. Lam AK. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol (2017) 28(3):213–27. doi: 10.1007/s12022-017-9484-5
2. Khatami F, Mohammadamoli M, Tavangar SM. Genetic and Epigenetic Differences of Benign and Malignant Pheochromocytomas and Paragangliomas (Ppgls). Endocr Regul (2018) 52(1):41–54. doi: 10.2478/embr-2018-0006
3. Nolting S, Grossman AB. Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies. Endocr Pathol (2012) 23(1):21–33. doi: 10.1007/s12022-012-9199-6
4. Fuehrlein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell (2017) 31(2):181–93. doi: 10.1016/j.ccell.2017.01.001
5. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate Links TCA Cycle Dysfunction to Oncogenesis by
43. Bizzarri N, De Cian F, Di Domenico S, Centurioni MG, Mammoliti S, Ghirardi V, et al. Peritoneal Carcinomatosis From Ovarian Paraganglioma: Report of a Rare Case and Systematic Review of the Literature. J Obstet Gynaecol Res (2018) 44(9):1682–92. doi: 10.1111/jog.13713

44. van Hulsteijn LT, Corssmit EP, Coremans IE, Smit JW, Jansen JC, Dekkers OM. Regression and Local Control Rates After Radiotherapy for Jugulotympanic Paragangliomas: Systematic Review and Meta-Analysis. Radiother Oncol (2013) 106(2):161–8. doi: 10.1016/j.radonc.2012.11.002

45. Fatima N, Pollok E, Soltys S, Chang SD, Meola A. Stereotactic Radiosurgery for Head and Neck Paragangliomas: A Systematic Review and Meta-Analysis. Neurosurg Rev (2020) 43(4):741–52. doi: 10.1007/s10143-020-01292-5

46. Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, et al. Efficacy and Safety of Ablative Therapy in the Treatment of Patients With Metastatic Pheochromocytoma and Paraganglioma. Cancers (Basel) (2019) 11(2):195. doi: 10.3390/cancers11020195

47. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG Therapy for Malignant Paraganglioma and Phaeochromocytoma: Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) (2014) 80(4):487–501. doi: 10.1111/cen.12341

48. Satapathy S, Mittal BR, Bhansali A. Peptide Receptor Radionuclide Therapy in the Management of Advanced Pheochromocytoma and Paraganglioma: A Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) (2019) 91(6):718–27. doi: 10.1111/cen.14106

49. Niemeijer ND, Albàs C, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy With Cyclophosphamide, Vincristine and Dacarbazine for Malignant Paraganglioma and Pheochromocytoma: Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) (2014) 81(5):642–51. doi: 10.1111/cen.12542

50. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Aghzul A, Caramella C, et al. SDHB Mutations are Associated With Response to Temozolomide in Patients With Metastatic Pheochromocytoma or Paraganglioma. Int J Cancer (2014) 135(11):2171–20. doi: 10.1002/ijc.28913

51. Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M, et al. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. J Clin Med (2020) 10(1):88. doi: 10.3390/jcm10010088

52. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, et al. Phase 2 Study of Pembrolizumab in Patients With Advanced Rare Cancers. J Immunother Cancer (2020) 8(1):e000347. doi: 10.1136/jitc-2019-000347

53. Leijon H, Remes S, Hagstrom J, Louhimin J, Maenpaa H, Schalin-Jantti C, et al. Variable Somatostatin Receptor Subtype Expression in 151 Primary Pheochromocytomas and Paragangliomas. Hum Pathol (2019) 86:66–75. doi: 10.1016/j.humpath.2018.11.020

54. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, et al. Somatostatin Receptor Type 2A Immunohistochemistry in Neuroendocrine Tumors: A Proposal of Scoring System Correlated With Somatostatin Receptor Scintigraphy. Mod Pathol (2007) 20(11):1172–82. doi: 10.1038/modpathol.0800954

55. Han S, Sub CH, Woo S, Kim YJ, Lee JY. Performance of (68)Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med (2019) 60(3):369–76. doi: 10.2967/jnumed.118.211706

56. van Hulsteijn LT, van Duinen N, Verbist BM, Jansen JC, van der Kleuwa AA, Smit JW, et al. Effects of Octreotide Therapy in Progressive Head and Neck Paraganglioma: Case Series. Head Neck (2013) 35(12):E391–6. doi: 10.1002/hed.23248

57. Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine Kinase Receptors as Molecular Targets in Pheochromocytomas and Paragangliomas. Mod Pathol (2014) 27(8):1050–62. doi: 10.1038/modpathol.2013.233

58. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JF, Plouin PF, Corvol P, et al. The R22X Mutation of the SDHD Gene in Hereditary Paraganglioma Abolishes the Enzymatic Activity of Complex II in the Mitochondrial Respiratory Chain and Activates the Hypoxia Pathway. Am J Hum Genet (2001) 69(6):1168–97. doi: 10.1086/324413

59. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs Cycle Intermediates and Over-Expression of HIF1alpha in Tumours Which Result From Germline FH and SDH Mutations. Hum Mol Genet (2005) 14(15):2231–9. doi: 10.1093/hmg/ddi227

60. Facchin C, Perez-Liva M, Garofalakis A, Vieil T, Certain A, Balvay D, et al. Concurrent Imaging of Vascularization and Metabolism in a Mouse Model of Paraganglioma Under Anti-Angiogenic Treatment. Theranostics (2020) 10(8):3518–32. doi: 10.7150/thno.40687

61. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med (2015) 17(5):405–24. doi: 10.1038/gim.2015.30

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.